First Horizon Advisors, Inc. Coherus Bio Sciences, Inc. Transaction History

First Horizon Advisors, Inc.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 10, 2022	SELL	$10.92 - $16.41 $5,263 - $7,909	-482 Closed	0 $0
Q2 2021 Aug 09, 2021	BUY	$12.95 - $15.41 $77 - $92	6 Added 1.26%	482 $6,000
Q1 2021 May 11, 2021	SELL	$14.42 - $21.39 $605 - $898	-42 Reduced 8.11%	476 $6,000
Q4 2020 Feb 11, 2021	BUY	$16.56 - $18.94 $1,391 - $1,590	84 Added 19.35%	518 $9,000
Q2 2020 Jul 31, 2020	BUY	$14.43 - $19.16 $6,262 - $8,315	434 New	434 $7,000

124

54.7M

291K

120K

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $92.5M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

Get notified when there are updates to the investment portfolio of First Horizon Advisors, Inc., based on Form 13F filings with the SEC.

Stay updated on First Horizon Advisors, Inc. with notifications on news.